Heron Therapeutics’ (HRTX) Buy Rating Reiterated at JMP Securities

heron-therapeutics8217-hrtx-buy-rating-reiterated-at-jmp-securities.png

Heron Therapeutics Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating reaffirmed by stock analysts at JMP Securities in a research report issued to clients and investors on Friday.
A number of other brokerages also recently weighed in on HRTX. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $41.00 price objective on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Lake Street Capital reaffirmed a “buy” rating and set a $45.00 price objective on shares of Heron Therapeutics in a report on Tuesday. Leerink Swann reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Thursday, August 18th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $47.70.
Heron Therapeutics (NASDAQ:HRTX) traded down 0.42% on Friday, hitting $18.79. 149,168 shares of the stock traded hands. The stock has a 50-day moving average price of $18.95 and a 200 day moving average price of $18.84. Heron Therapeutics has a 12-month low of $15.22 and a 12-month high of $42.25.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/heron-therapeutics-hrtx-buy-rating-reiterated-at-jmp-securities.html

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Equities analysts expect that Heron Therapeutics will post ($4.41) earnings per share for the current year.
In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total value of $2,330,000.00. Following the completion of the sale, the insider now owns 102,640 shares in the company, valued at approximately $2,391,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.31% of the stock is currently owned by company insiders.
A number of large investors recently bought and sold shares of HRTX. Brandywine Global Investment Management LLC bought a new stake in Heron Therapeutics during the fourth quarter valued at $2,162,000. Franklin Resources Inc. boosted its stake in Heron Therapeutics by 28.2% in the first quarter. Franklin Resources Inc. now owns 7,523,278 shares of the biotechnology company’s stock valued at $142,869,000 after buying an additional 1,653,008 shares during the last quarter. BlackRock Group LTD boosted its stake in Heron Therapeutics by 174.2% in the first quarter. BlackRock Group LTD now owns 9,919 shares of the biotechnology company’s stock valued at $188,000 after buying an additional 6,301 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Heron Therapeutics by 1.4% in the first quarter. Geode Capital Management LLC now owns 207,789 shares of the biotechnology company’s stock valued at $3,945,000 after buying an additional 2,908 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Heron Therapeutics’ (HRTX) Buy Rating Reiterated at JMP Securities"

Leave a comment

Your email address will not be published.


*